A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/435 (2006.01) A61K 31/40 (2006.01) A61K 31/405 (2006.01)
Patent
CA 2294399
The present invention relates to a pharmaceutical composition for the treatment of cancer or a benign proliferative disorder in a mammal, comprising an FTase inhibitor, an HMG CoA reductase inhibitor and a pharmaceutically acceptable carrier, wherein the FTase inhibitor and the HMG CoA reductase inhibitor are present in amounts that render the composition effective in the treatment of cancer of a benign proliferative disorder in a mammal. The present invention also relates to a pharmaceutical composition for inhibiting the abnormal growth of cells in a mammal, comprising an FTase inhibitor, an HMG CoA reductase inhibitor and a pharmaceutically acceptable carrier, wherein the FTase inhibitor and the HMG CoA reductase inhibitor are present in amounts that render the composition effective in the inhibitor of growth of abnormal cells in a mammal.
La présente invention concerne un procédé se rapportant au traitement anticancéreux chez un mammifère, et notamment les humains, et consistant en l'administration, à ce mammifère, d'un inhibiteur de FTase associé à un inhibiteur de HMG CoA réductase.
Pfizer Products Inc.
Smart & Biggar
LandOfFree
Farnesyl transferase inhibitors in combination with hmg coa... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Farnesyl transferase inhibitors in combination with hmg coa..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesyl transferase inhibitors in combination with hmg coa... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1465944